肿瘤患者ABCB1基因多态性与紫杉醇疗效及药物不良反应的相关性研究  

Research on the correlation between ABCB1 genes polymorphism in tumor patients and the efficacy and adverse drug reactions of paclitaxel

作　　者：许秋霞[1] 何少斌 张吟[1] 陈金成[1] 吴沁 庄奕筠[1] XU Qiu-xia;HE Shao-bin;ZHANG Yin;CHEN Jin-cheng;WU Qin;ZHUANG Yi-jun(Laboratory of Clinical Pharmacy,Department of Pharmacy,The Second Affiliated Hospital of Fujian Medical University,Quanzhou362000,Fujian Province,China;Departmetntof Pharmacy,Fujian Provincial Hospital,Fuzhou 350001,Fujian Province,China)

机构地区：[1]福建医科大学附属第二医院药学部临床药学实验室,福建泉州362000 [2]福建省立医院药学部,福建福州350001

出　　处：《中国临床药理学杂志》2023年第17期2450-2454,共5页The Chinese Journal of Clinical Pharmacology

基　　金：福建省科技厅社会发展引导性(重点)基金资助项目(2015Y0055);福建省卫计委青年科研课题基金资助项目(2015-1-60);泉州市引进高层次人才团队基金资助项目(2023CT008)。

摘　　要：目的 探讨肿瘤患者腺苷三磷酸结合盒B家族成员1(ABCB1)基因多态性与紫杉醇疗效及药物不良反应的相关性。方法 选取接受紫杉醇化疗的肿瘤患者作为研究对象,检测其ABCB1 T3435C、C1236T、G2677T/A基因型,并将患者分为野生型组和突变型组。2个周期后,对疗效和药物不良反应进行评估,分析患者的疗效及药物不良反应和ABCB1基因多态性的相关性。结果 67例肿瘤患者中,ABCB1 G2677T/A基因的野生型组的有效率(69.23%)高于突变型组(25.93%),差异有统计学意义(P<0.05);在药物不良反应指标中,ABCB1 G2677T/A基因的野生型组的谷丙转氨酶(21.42±6.93)U·L^(-1)低于突变型组(28.80±17.96)U·L^(-1),两者存在显著性差异(P<0.05)。而ABCB1 C3435T、C1236T基因的野生型组、突变型组之间的疗效和药物不良反应均不存在显著性差异(均P>0.05)。结论 ABCB1 G2677T/A基因多态性与紫杉醇的疗效和肝毒性具有相关性,而ABCB1 C3435T、C1236T基因多态性与紫杉醇的疗效和药物不良反应均不具有相关性。Objective To investigate the relationship between adenosine triphosphate-binding cassette subfamily B member 1(ABCB1)gene polymorphism and the efficacy and adverse drug reactions of paclitaxel in tumorpatients.Methods Tumorpatientssreceivingpaclitaxel chemotherapy were selected as research objects,and their ABCB1 T3435C,C1236T,G2677T/A genotypes were detected,and the patients were divided into wild type group and mutant group.After 2 cycles,the efficacy and adverse drug reactions were evaluated,and the correlations between the efficacy and adverse drug reactions and ABCBl gene polymorphism were analyzed.Results Among 67 tumor patients,the effective rate of ABCB1 G2677T/AA gene in the wild type group(69.23%)was higher than that in the mutant group(25.93%),with a significant difference between them(P<0.05).In the index of adverse drug reactions,glutamic-pyruvic transaminase(21.42±6.93)U·L^(-1) in the wild type group of ABCB1 G2677T/A gene was lower than that in the mutant group(28.80±17.96)U.L^(-1),with significant difference between the two groups(P<0.05).There were no significant differences in efficacy and adverse drug reactions between wild type and mutant ABCB1 C3435T and C1236T gene groups(P>0.05).Conclusion ABCB1 G2677T/A gene polymorphism is associated with the efficacy and hepatotoxic adverse drug reaction of paclitaxel,while ABCB1 C3435T and C1236T gene polymorphisms were not associated with the efficacy and adverse drug reactions of paclitaxel.

关 键 词：紫杉醇 腺苷三磷酸结合盒B家族成员1 基因多态性 疗效 药物不良反应 

分 类 号：R979.1[医药卫生—药品]